Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York
Source: Streetwise Reports  (2/27/25)
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.

More >

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery
Source: Streetwise Reports  (2/14/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.

More >

Healthcare Tech Co. To Acquire Digital Health Platform
  (2/13/25)
This will expand its ecosystem of AI-powered products. Read on to learn more about its offerings and rapidly growing sector. More >

New Strategic Moves Aim To Accelerate Growth in AI Healthcare
Source: Streetwise Reports  (2/12/25)
Light AI Inc. (ALGO:CBOE) announces major marketing campaigns, advisory board appointments, and a key regulatory partnership to drive growth. Discover how these strategic moves could shape the future of AI healthcare.

More >

Kentucky Medical Co. Has Strong Operating Fundamentals
Source: Douglas Loe  (2/12/25)
Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note. More >

AI Stock in an Uptrend That Is Likely To Continue
Source: Clive Maund  (2/10/25)
Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy. More >

Healthcare Pioneer Expands Revolutionary Treatment Platform
Source: Streetwise Reports  (2/6/25)
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development." More >

Biotech Requests OK to Assess Device in Second Indication
Source: Dr. Joseph Pantginis  (2/6/25)
The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report. More >

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease
Source: Douglas Lowe  (2/4/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company. More >

Washington D.C. Pharma Co. Receives FDA Acceptance
Source: Dr. Ram Selvaraju  (1/28/25)
Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst. More >

Biotech's Target Price 183.757% Higher Than Current
Source: Jason Kolbert  (1/24/25)
Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price. More >

AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery
Source: Streetwise Reports  (1/23/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) highlights the transformative potential of the US$500 billion Stargate Initiative, set to revolutionize AI-driven drug discovery. Learn how this landmark investment could redefine oncology breakthroughs.

More >

Biopharma Shares Multiple 2025 Catalysts
Source: Dr. Swayampakula Ramakanth  (1/17/25)
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co. More >

Advanced AI Solutions Deliver Hope for CNS Cancer Treatment
Source: Streetwise Reports  (1/15/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation. More >

Tech Innovator Achieves Breakthrough Multi-Market Success
Source: Streetwise Reports  (1/15/25)
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock. More >

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections
Source: Streetwise Reports  (1/10/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research. More >

Biotech Advances Breakthrough Cancer Treatment Results
Source: Francois Brisebois  (1/10/25)
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note. More >

Pharma Innovator Reveals Groundbreaking Diabetes Treatment
Source: Jason Kolbert  (1/10/25)
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share. More >

Should You Double Down on This Story Stock?
Source: Chris Temple  (1/7/25)
Chris Temple of The National Investor explains why he believes you might want to double down on BioLargo Inc. (BLGO:OTCQX). More >

AI Company Unlocks Breakthrough Medical Diagnostics Platform
Source: Streetwise Reports  (1/6/25)
One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide. More >

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech
Source: Streetwise Reports  (1/6/25)
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence. More >

Pharma Innovator Unlocks Multi-Disease Treatment Potential
Source: Jason Kolbert  (1/3/25)
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. More >

Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Source: Sean Lee  (1/3/25)
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. More >

Miami Biopharma Sells Part of Business and Begins New Clinical Trial
Source: Dr. Yi Chen  (1/2/25)
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. More >

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug
Source: Ed Arce  (12/31/24)
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target. More >